WO2004043436A1 - Aerosol a usage medical comprenant une huile essentielle provenant d'une plante et sa preparation - Google Patents

Aerosol a usage medical comprenant une huile essentielle provenant d'une plante et sa preparation Download PDF

Info

Publication number
WO2004043436A1
WO2004043436A1 PCT/CN2003/000964 CN0300964W WO2004043436A1 WO 2004043436 A1 WO2004043436 A1 WO 2004043436A1 CN 0300964 W CN0300964 W CN 0300964W WO 2004043436 A1 WO2004043436 A1 WO 2004043436A1
Authority
WO
WIPO (PCT)
Prior art keywords
oil
acetate
ethyl
aerosol
methyl
Prior art date
Application number
PCT/CN2003/000964
Other languages
English (en)
Chinese (zh)
Inventor
Fanzi Cong
Original Assignee
Fanzi Cong
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from CNA021483914A external-priority patent/CN1500477A/zh
Priority claimed from CNA031040314A external-priority patent/CN1520846A/zh
Application filed by Fanzi Cong filed Critical Fanzi Cong
Priority to AU2003284806A priority Critical patent/AU2003284806A1/en
Publication of WO2004043436A1 publication Critical patent/WO2004043436A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/13—Coniferophyta (gymnosperms)
    • A61K36/15—Pinaceae (Pine family), e.g. pine or cedar
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/57—Magnoliaceae (Magnolia family)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/61—Myrtaceae (Myrtle family), e.g. teatree or eucalyptus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
    • A61K36/738—Rosa (rose)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/75—Rutaceae (Rue family)
    • A61K36/752—Citrus, e.g. lime, orange or lemon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy

Definitions

  • the present invention relates to an aerosol suitable for oral and / or nasal inhalation and a method for preparing the same.
  • asthma aerosols commonly used are salbutamol aerosols, salmeterol aerosols, clenbuterol aerosols, ipratropium bromide aerosols, and sodium cromoglycate Aerosols, Diffrolin aerosols, beclometasone propionate aerosols, budesonide aerosols, Chuantai aerosols and Copiter aerosols, etc. No tuberculosis prevention has been seen And therapeutic aerosols, and aerosols administered to the brain through the nasal cavity are rarely seen.
  • Aromatherapy is derived from the French terms Aroma and Therapy.
  • the main supplies for aromatherapy are essential oils (Es sent ial Oil) extracted from plants, also called aroma oils.
  • the flowers, fruits, roots, stems, and leaves of some higher plants in nature all have unique botanical aromas.
  • These are the essential oils that the plants receive from the solar energy and convert the energy of the sun through photosynthesis.
  • These essential oils exist in the intercellular spaces of plants in the form of tiny drops, and play the role of plant life
  • the role of hormones can help plants adapt to their surroundings and resist disease and pests.
  • Essence oil contains the motive power of plant life.
  • many essence oils are similar to human hormones in nature and have important effects on the human body, such as regulating nervous system, endocrine system, digestion and excretion system, and enhancing immune function, promoting cell regeneration. .
  • Psychological activity the activation of the nervous system, and the functioning of the immune system are interrelated.
  • the immune system is the main guarantee of human health. The easiest thing for people to realize and try to master is psychological activity.
  • Psycho-neuroimmunology is a new discipline that studies the effect of "sense” (psychology) on the immune system. Good “sense” can make the body Good condition, and psychological activity plays an extremely important role in the whole process of disease occurrence and elimination (see Figure 1).
  • the researchers of the present invention have conducted repeated experiments and studies, and found that, by adding a small amount of natural aromatic fragrance to the traditional medical aerosol, the above-mentioned problem of docking the aroma therapy with the patient can be solved.
  • the purpose of the present invention is to improve the mood (psychology) of patients, balance the autonomic nerve function, restore the ability of the nervous medium, endocrine system and immune system of the body by using the overall concept of traditional Chinese medicine and aromatherapy methods, to complement and assist traditional medical gas from a macro perspective.
  • the original drug of the aerosol can achieve the purpose of treating the specimens simultaneously.
  • a new way is opened for the conversion of propellants from CFCs to HFCs.
  • Figure 1 is a schematic diagram of the psychological immune mechanism of a bronchial asthma attack. This picture is taken from China Medical Science and Technology Press, April 1997.
  • the medical aerosol of the present invention contains the following components:
  • Two-phase aerosol or three-phase suspension aerosol carrier 5 Zero, one or more solvents,
  • the fast-acting medical aerosol with a plant aroma of the present invention contains a natural aromatic fragrance having a fragrant effect, and the amount of the natural aromatic fragrance having a fragrant effect is 0.000001 ppm to 5 based on the total weight of the aerosol content %.
  • the natural aromatic fragrance with aromatherapy effect is selected from the non-toxic, single-use, plant essence oils contained in natural plants with aromatic flavors and flavoring agents and odorant agents that can be used as medicines, foods, cosmetics and high-end perfumes. Or it can be used in combination to produce a fresh, pleasant, serene, comfortable and refreshing natural fragrance and crude extracts of natural fragrances, refined extracts and synthetic compounds derived from refined extracts, more preferably used alone Or after being used in combination, the plant essence oil and its extract which also have a drug penetration promotion effect and / or a suspension effect in the aerosol.
  • Botanical essence oil, natural flavors and crude extracts of natural flavors contained in natural plants with aromatherapy effects are selected from one or more of the following: (bitter) orange leaf (Pet i tgrain bigarade and Paraguay) oil , Oil of Geranium Jamaican, Ardisia Leaf oil, Oil of Tansy, Artemisia argyi oil, Benzoin oil, Eucalyptus oil ), Australian Sandalwood Austral i an, Aniseed star and Anise oil, oil of Brazilian
  • Sassafras Oil of Bo is de Rose Brazi 1 ian, Oil of Calamus, oil of Cajeput, white ochre oil, Oil of Michelia Alba Flower , Oil of Michelia Alba Leaf, Oil of Michelia Alba Leaf, Atractylodes oil, Baisu oil, Baiwei oil, Baiji oil, Oil of Thyme, Oil of Cedar leaf, Cypress Cedarwood oil, cypress kernel oil, pinellia oil, sassafras oil, Beisha ginseng oil, Oil of Cubeb, psoralea oil, cardamom oil, grass fruit oil, and tea tree oil (Oil of Tea Tree) ), Atractyllis oil, Bupleurum oil, Agarwood oil, Chenpi oil, Chihu oil, Chuanmu oil, Chuanxiong oil, Camomile oil (UK type) (Oil of Chamomile English Type), oil of Juniper Berries, Dalmatian sage oil (Oil of Sage Dalmati
  • Oil of Ylang Ylang Complete Oil of Ylang Ylang, Oil of Ylang Ylang, Oil of Mandarin Italy, Immortelle Oil, Yin Chen Oil, Epimedium Oil, Oil of Abies Alba, Oil of Dill Seed Indian, Oil of Dillweed American, Eucalypus Oil, Corn Beard Oil, Turmeric Oil , Oil of Guaiacwood, Oil of Orris Root, Oil of Lovage, Oil of Grapefruit Expressed, Oil of Grapefruit Expressed Bay Leaf), Laurel Leaf Oil (Oil of Laurel Leaf), Evening Primrose Oil, Oil of Spruce, Oil of Rue, Oil of Lavandin, Oil of Lavandin, France) (Oil of Lavandin Abrialis (France)), Zeeland Oil, Oil Of Camphor 1070, Oil of Camphor White 860-880, Distilled White Lemon Oil (Oil of Lime Distilled), Distilled Seed Oil emon Distilled), Distilled Sweet Orange Oil (Oil of Orange Distilled), Fat Sandalwood
  • the compound is selected from one or more of the following: (chlorine-free) benzyl acetate, “nerolione”, “hyacinthin”, “citraldehyde”, “eucalin”, “lilyanal””,” Jasmine ester ",” principal aldehyde “,” bergamot “,” neolivalin “,” myric aldehyde “, 1, 8-eucalyptus, 2, 6-dimethylheptene-5 -Aldehyde-1, 2, 7, 8-trimethylcyclododecatriene-2, 5, 9-fluorenylmethanone, 2-ethylhexanal cycloethylene diacetal, 3,3-dimethyl Cyclohexylmethylfluorenone, 3-methylindole, 404 fixative, 5-phenyl-5-fluorenylhexanone-3, 6-methylquinoline, 6-methyltetrahydroquinoline, N -Methyl ethyl anthranil
  • a cold is a local infection of the nasal mucosa. Under normal circumstances, viruses and bacteria do not enter the blood. Oral and injection treatments are not as effective as local administration. Rhinitis and allergic rhinitis mainly show local symptoms. Need to be administered locally; sore throat and tonsillitis are often given clinically in grass coral tablets and throat protection (oral sugar), which is not the fundamental solution to the problem, because the active ingredients of these two dosage forms are accompanied by saliva When the pharynx passes through the pharynx and cannot reach the throat, it cannot cure the throat and requires local spray administration.
  • Subtopical drugs such as: respiratory, circulatory, inhalation via the nasal cavity, oral cavity, and lungs are faster than oral administration and have a longer duration of action. Therefore, subtopical administration is required.
  • nasal cavity is a part of the cranium with many small holes.
  • the endothelium of the nasal cavity is like a sieve-like plate through which the nerve bundles are filled with cerebrospinal fluid.
  • Part of the drug Can enter the cerebrospinal fluid. Because this route of administration is more convenient and painless than bottom push injection. Therefore, when drug delivery to the brain is required, nasal spray administration should be preferred.
  • Drugs for systemic administration are needed. Many drugs are degraded before they enter the systemic circulation, including gastrointestinal degradation and metabolism, and first-pass effects in the liver. These factors lead to reduced bioavailability and short duration of action. In recent years, studies have found that the bioavailability of many drugs for nasal administration is higher than that for oral administration. Especially with the development of biotechnology, more and more biochemical drugs (protein and peptide drugs) are used to treat various diseases, and these drugs cannot generally be administered orally, and some of them are not suitable for parenteral routes. For long-term treatment. As a result, more and more formulation experts are turning their attention to nasal, oral, and pulmonary drug delivery systems.
  • Drugs for local nasal administration and administration to the brain through the nasal cavity include, but are not limited to: anti-inflammatory drugs, local anesthetics, antiallergic drugs, antipyretic and analgesics, central stimulants, analgesics, antitremor paralysis drugs, antipsychotics Arrhythmics, antiepileptics, sedatives, hypnotics, anticonvulsants, intracranial pressure-lowering drugs, anti-brain tumor drugs, anti-senile dementia drugs.
  • Sub-locally administered drugs through the respiratory tract include, but are not limited to: asthma drugs, anti-tuberculosis drugs, anti-angina drugs.
  • Antiasthmatic medications include, but are not limited to: sodium cromoglycate, buprenorphine, beclometasone, fluticasone, budesonide, salbutamol, levosalbutamol, salmeterol, clenbuterol, procaterol, promethicol, tol Loterol, fenoterol, cloprolin, isoproterenol, bibutrol, hysonalin, osinalin, terbutaline, flutopramine, nedocrolim sodium, isopropyl Tobronium bromide, iprascopolamine, or physiologically acceptable salts, esters, solvates thereof; anti-tuberculosis drugs include, but are not limited to: sodium isoniazid sulfonate, isoniazid, pyrazinamide, rifampicin, rifampicin Fuding, rifapentin, rifamycin, ethionamide, str
  • non-peptide and non-protein drugs mainly include anti-inflammatory steroids or non-steroidal anti-inflammatory drugs, analgesic anti-inflammatory agents, antitussive and expectorants, antihistamines, antiallergic drugs, antiemetics, vitamin preparations, Sexual steroid hormones, antitumor drugs, antihypertensive drugs, antiulcer drugs, obesity agents, antithrombotic drugs, antidiabetic drugs, muscle relaxants, antirheumatic drugs;
  • peptides, protein drugs, vaccines mainly include Insulin, glucagon and its derivatives, insulin C-peptide, vasopressin, desmopressin, adrenocorticotropin and its derivatives, adrenocorticotropin-releasing hormone, soothing kallikrein derivatives, Gonadotropin-releasing hormone, gonadotropin-releasing hormone agonists
  • the present invention does not specifically limit the medicine in the aerosol, as long as it can be used for oral and / or nasal inhalation of aerosol administration, for example, it can be used for local administration in the nasal cavity
  • a drug administered to the brain through the nasal cavity a drug administered sub-locally to the lungs or heart through the respiratory tract, and a drug administered systemically through the respiratory tract.
  • the amount of the drug to be used in the aerosol is not particularly limited, and can be appropriately determined according to the age, sex, weight, symptoms, and degree of disease of the patient. Generally, the amount of the drug is 0.0001-10% of the total weight of the aerosol contents.
  • the medical aerosol of the present invention may further contain a drug penetration enhancer.
  • a drug penetration enhancer There is no particular limitation on the drug penetration enhancer and the amount thereof. Commonly used drug penetration enhancers may be used, for example, decyl One or two or more of acids, lauric acid, laurone, citrate, lecithin, cholate, etc. The amount is generally 0 to 5% of the total weight of the aerosol content.
  • the medical aerosol of the present invention may not contain the above-mentioned drug penetration enhancer, that is, in the presence of a natural plant essence oil having an aromatherapy effect, it may have a function of promoting drug penetration even if no additional drug penetration enhancer is added. This is because most of the natural plant essence oil with aromatherapy effect added in the present invention has the effect of promoting drug penetration.
  • the medical aerosol of the present invention may be a two-phase aerosol or a three-phase suspension aerosol.
  • the carrier constituting the aerosol, and commonly used medicines can be used.
  • the carrier may include: a latent solvent, such as glycerol, polyethylene glycol, propylene glycol, etc., the amount of which is Q-5% of the total weight of the aerosol content; a solvent such as ethanol, propanol, isopropyl alcohol Propanol, ethyl acetate, etc.
  • 1,1,1,2-tetrafluoroethane F134a
  • 1, 1, 1, 2, 3, 3, 3-heptafluoropropane F227ea
  • difluoroethane F152a
  • trichloromonofluoromethane F11
  • dichlorodifluoromethane F12
  • dichlorotetrafluoroethane Fll 4
  • dichloromonofluoroethane Fl 4 lb
  • monofluorodichloroethane Fl b
  • more preferably 1, 1, 1, 2-tetrafluoroethane, 1 1,1,2,3,3,3-heptafluoropropane in an amount of 50-95% of the total weight of the aerosol content preferably 1, 1, 1, 2-tetrafluoroethane, 1 1,1,2,3,3,3-heptafluoropropane in an amount of 50-95% of the total weight of the aerosol content.
  • its carrier may include: suspending agents, such as oleic acid, oleyl alcohol, Span-85, Span-80, Span-65, Span-60, Span-40 , Span-20, Tween-80, Tween-40, Tween-40, Lecithin, Brij35, Bri j30 and other surfactants, the amount of which is 0-5% of the total weight of the aerosol content; , Such as ethanol, propanol, isopropanol, ethyl acetate, glycerol, polyethylene glycol, propylene glycol, evening primrose oil, corn oil, sunflower oil, soybean oil, the amount used is 0- 20 %; propellant, l, l, l, 2 -tetrafluoroethane (F134a), 1, 1, 1, 2, 3, 3, 3-heptafluoropropane (F227ea), difluoroethane (F152a) ), Trichloro
  • suspending agents such as oleic
  • the medical aerosol of the present invention may not contain the above-mentioned suspending agent, that is, in the presence of a natural plant essence oil having an aromatherapy effect, the aerosol can be made without adding an additional suspending agent. It is because most of the natural plant essence oils with aromatherapy effect added by the present invention have a suspension effect.
  • each medical aerosol is best made into three or more aerosols with different aromas to meet the preferences of different patients (the patients have different etiology and pathogenesis, the preferences are different), and can prevent the long-term use of a single The olfactory fatigue caused by the aroma (or the pathogenesis has changed).
  • the medical aerosol of the present invention can be prepared by a conventional method.
  • Two-phase aerosol When it is used as an agent, its preparation can be completed through several steps such as batching, adjusting, dispensing, glandizing, and filling with propellant.
  • natural fragrances and drug penetration enhancers with aromatherapy effects can be added directly to the solvent, or they can also be added through a propellant.
  • the solid pharmaceutical fine powder is suspended in a pressure-resistant container at a low temperature in a natural aromatic fragrance containing a suspending agent and having an aromatherapy effect, a drug penetration enhancer, and a latent solvent.
  • the mixed solution of the propellant and the propellant the mixed liquid is directly and quantitatively injected into the closed container covered with the quantitative valve through the valve on the lid after the mixing is uniformly hooked.
  • spray drying method controlled crystallization method, air-flow type pulverization method, or oscillating ultrafine pulverization method can be selected to pulverize the particle size of solid materials to less than 5 ⁇ m when administered to the lungs, and the nasal cavity Crush to less than 20 ⁇ m at the time of administration.
  • the entire production process before capping should be controlled for temperature, humidity and moisture, with the temperature below 20 ° C and the humidity below 40% relative humidity.
  • the solvent, latent solvent and propellant should be dewatered before use, and the water content of the finished product should be controlled below 300PPM. If the temperature is high, the uniformity of the product is poor.
  • the stability of the product will be affected.
  • the drug penetration enhancer and the drug suspension agent are not selected from the commonly used surfactants, but are selected together with natural aromatic fragrances having aromatherapy effects, and the plant essence oil with aromatic aroma is used, in the production process of preparing aerosols,
  • the humidity of the environment does not need to be strictly controlled, and the relative humidity is less than 85%. At this time, a small amount of moisture will not affect the stability of the product.
  • the advantage of the present invention is that the plant essence oil selected in the present application is both a suspending agent and a drug penetration enhancer in the prescription, and also has the most fashionable aromatherapy effect in the world at present, and the Trinity.
  • the plant essence oil in the medical aerosol of the present invention has a suspension-assisting effect, which can make the particle size distribution in the aerosol more uniform, thereby further increasing the internal shield amount of the aerosol; and the rapid effect formed by its penetration promoting effect Can shorten the patient's difficult time from 5 to 15 minutes after the onset of the disease; its aromatherapy effect can correspondingly eliminate the psychological and physical discomfort of the patient at the time of the disease, adjust the body's immune ability, and give the patient the drug Feels immediate.
  • the aroma of plants with aromatherapy can immediately stimulate olfactory cells, influence the excitatory and inhibitory activities of the cerebral cortex through mediators, improve the patient's psychological state, balance autonomic nerve functions, restore the body's neural mediators, the endocrine system, and Immune system ability, macroscopically supporting and assisting traditional medical aerosol original drugs to achieve the purpose of treating the symptoms and roots (improving the body's aroma, balance, and recovery are the root causes of the disease, such as asthma drugs, etc., are the symptoms and symptoms. ).
  • the volatile oil also overcomes the possibility of adhesion between the granules during spray administration due to the oily viscosity of surfactants such as Span-85.
  • 20 g of albuterol pulverized to less than 5 ⁇ m and 20 g of anhydrous sodium sulphate by air jet pulverizer or oscillating pulverizer, added at low temperature and high pressure and mixed Hejungou contains 15g of peppermint oil, 10g coltsfoot oil, lOOg of evening primrose oil and 13,800g of 1,1,1,2-tetrafluoroethane mixture. Stir thoroughly to make them even. After passing the inspection, , Dispense into 1000 sealed aluminum hall bottles through the valve on the lid, and inject 14 g of mixed chemical solution into each bottle.
  • Bailan Leaf Oil 10g
  • Frankincense Oil 10g
  • Anhydrous Sodium Sulfate 20g
  • Ethanol 150g 1, 1, 1, 2-Tetrafluoroethane Pit 13800g
  • 900 g of isoniazid pulverized to less than 5 ⁇ m, 50 g of anhydrous sodium sulfate, and 20 g of peppermint oil, 30 g of eucalyptus oil, 10 g of lavender oil, and 300 g of evening primrose oil are mixed with an air grinder or an oscillating grinder. After passing the inspection, it is divided into 1000 aluminum hall bottles, the cap body with a quantitative valve is capped, and 12.7 g of 1, 1, 1, 2-tetrafluoroethane per bottle is injected through the valve on the cap body. 1, 1, 1, 2, 3, 3, 3- heptafluoropropane is obtained.
  • Lavender Oil 10g Peppermint Oil 10g Perilla Oil 10g Evening primrose oil 300g 1,1,1,2-tetrafluoroethane 13600g Preparation process:
  • influenza composite subunit vaccine crushed to less than 5 ⁇ with 10g of peppermint oil, 10g of lavender oil, 10g of sage oil, and 300g of evening primrose oil. After passing the inspection, distribute them in 1000 aluminum halls.
  • a cap body with a quantitative valve is capped, and 13.6 g of 1, 1, 1, 2-tetrafluoroethane is injected into each bottle through the valve on the cap body.
  • the fast-acting salbutamol three-phase suspension aerosol was prepared by using the prescription and preparation method of Example 4 and tested by 12 volunteers who have used albuterol three-phase suspension aerosol. Volunteers all believe that the product of the present invention is significantly superior to the original albuterol aerosol product, which is specifically manifested as follows: After the aerosol spray of the present invention is administered, a cool and comfortable feeling is immediately produced in the respiratory tract. When exhaling slowly through the nasal cavity after a few seconds of breath holding, the stimulation of the olfactory cells by the aroma will give people a fresh, comfortable, and peaceful feeling; re-administer after 1 minute, and wait for the completion of the spray and inhalation. Asthmatic symptoms in post-sensitivity patients can be basically controlled; generally, asthma symptoms can be relieved in 2 to 5 minutes.

Landscapes

  • Health & Medical Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Botany (AREA)
  • Biotechnology (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Disinfection, Sterilisation Or Deodorisation Of Air (AREA)

Abstract

La présente invention se rapporte à un aérosol à usage médical comprenant un parfum naturel et sa préparation. Le parfum naturel est de préférence une huile essentielle à base d'une plante. Cette huile utilisée sert d'agent de suspension, d'amplificateur de pénétration et s'utilise dans le domaine de l'aromathérapie. L'aérosol ne contient pas de chlorofluorocarbure et est en mesure de réconforter les patients malades.
PCT/CN2003/000964 2002-11-13 2003-11-13 Aerosol a usage medical comprenant une huile essentielle provenant d'une plante et sa preparation WO2004043436A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2003284806A AU2003284806A1 (en) 2002-11-13 2003-11-13 Medicinal aerosol comprising plant essential oil and its preparation

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
CN02148391.4 2002-11-13
CNA021483914A CN1500477A (zh) 2002-11-13 2002-11-13 带有植物芳香气息的速效气雾剂及其制备方法
CNA031040314A CN1520846A (zh) 2003-02-13 2003-02-13 带有植物芳香气息的速效气雾剂及其制备方法
CN03104031.4 2003-02-13

Publications (1)

Publication Number Publication Date
WO2004043436A1 true WO2004043436A1 (fr) 2004-05-27

Family

ID=32313437

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2003/000964 WO2004043436A1 (fr) 2002-11-13 2003-11-13 Aerosol a usage medical comprenant une huile essentielle provenant d'une plante et sa preparation

Country Status (2)

Country Link
AU (1) AU2003284806A1 (fr)
WO (1) WO2004043436A1 (fr)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102370673A (zh) * 2010-08-23 2012-03-14 王登之 苏冰(速效救心)喷雾剂及其制备方法
CN104288813A (zh) * 2013-09-30 2015-01-21 昆山市巴城镇顺拓工程机械配件厂 一种空气清新剂
CN115414341A (zh) * 2022-09-14 2022-12-02 中国农业大学 一种包含α-紫罗兰酮用于抗紫外线暴露引起肾脏损伤的组合物
BE1030599B1 (fr) * 2022-11-23 2024-01-09 Erck Emmanuelle Van Composition à base d'huiles essentielles pour le traitement et la prévention des maladies inflammatoires des voies aériennes chez les animaux

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104815026A (zh) * 2015-03-12 2015-08-05 林翔云 一种催眠精油组合物

Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0365119A2 (fr) * 1988-08-27 1990-04-25 FISONS plc Composition pharmaceutique
JPH0372433A (ja) * 1989-04-28 1991-03-27 Hisamitsu Pharmaceut Co Inc 泡状エアゾール製剤
CN1063042A (zh) * 1991-01-11 1992-07-29 丛繁滋 双黄连气雾剂的制备方法
CN1096672A (zh) * 1993-06-22 1994-12-28 丛繁滋 温通开窍气雾剂及其制备方法
JPH09143098A (ja) * 1995-11-24 1997-06-03 Natl Sci Council 抗ウイルス剤アシクロビルの経皮吸収製剤
CN1153057A (zh) * 1996-05-17 1997-07-02 云南白药实业股份有限公司 云南白药气雾剂及其制备方法
JP2001233761A (ja) * 2000-02-18 2001-08-28 Yasunobu Yoshida 負イオン発生機による医薬品等の体内投与方法及び装置
WO2001095900A1 (fr) * 2000-06-15 2001-12-20 Ad 'zdravlje' Farmaceutsko - Hemijska Industrija, Centar Za Istrazivanje I Razvoj Desinfectants pharmaceutiques contenant de l"acide usnique et des huiles essentielles
JP2002241310A (ja) * 2001-02-21 2002-08-28 Taisho Pharmaceut Co Ltd 局所適用組成物
JP2002370977A (ja) * 2001-06-15 2002-12-24 Taisho Pharmaceut Co Ltd 局所適用組成物

Patent Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0365119A2 (fr) * 1988-08-27 1990-04-25 FISONS plc Composition pharmaceutique
JPH0372433A (ja) * 1989-04-28 1991-03-27 Hisamitsu Pharmaceut Co Inc 泡状エアゾール製剤
CN1063042A (zh) * 1991-01-11 1992-07-29 丛繁滋 双黄连气雾剂的制备方法
CN1096672A (zh) * 1993-06-22 1994-12-28 丛繁滋 温通开窍气雾剂及其制备方法
JPH09143098A (ja) * 1995-11-24 1997-06-03 Natl Sci Council 抗ウイルス剤アシクロビルの経皮吸収製剤
CN1153057A (zh) * 1996-05-17 1997-07-02 云南白药实业股份有限公司 云南白药气雾剂及其制备方法
JP2001233761A (ja) * 2000-02-18 2001-08-28 Yasunobu Yoshida 負イオン発生機による医薬品等の体内投与方法及び装置
WO2001095900A1 (fr) * 2000-06-15 2001-12-20 Ad 'zdravlje' Farmaceutsko - Hemijska Industrija, Centar Za Istrazivanje I Razvoj Desinfectants pharmaceutiques contenant de l"acide usnique et des huiles essentielles
JP2002241310A (ja) * 2001-02-21 2002-08-28 Taisho Pharmaceut Co Ltd 局所適用組成物
JP2002370977A (ja) * 2001-06-15 2002-12-24 Taisho Pharmaceut Co Ltd 局所適用組成物

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102370673A (zh) * 2010-08-23 2012-03-14 王登之 苏冰(速效救心)喷雾剂及其制备方法
CN104288813A (zh) * 2013-09-30 2015-01-21 昆山市巴城镇顺拓工程机械配件厂 一种空气清新剂
CN115414341A (zh) * 2022-09-14 2022-12-02 中国农业大学 一种包含α-紫罗兰酮用于抗紫外线暴露引起肾脏损伤的组合物
CN115414341B (zh) * 2022-09-14 2023-04-11 中国农业大学 一种包含α-紫罗兰酮用于抗紫外线暴露引起肾脏损伤的组合物
BE1030599B1 (fr) * 2022-11-23 2024-01-09 Erck Emmanuelle Van Composition à base d'huiles essentielles pour le traitement et la prévention des maladies inflammatoires des voies aériennes chez les animaux

Also Published As

Publication number Publication date
AU2003284806A1 (en) 2004-06-03

Similar Documents

Publication Publication Date Title
CN1500477A (zh) 带有植物芳香气息的速效气雾剂及其制备方法
Michalak Aromatherapy and methods of applying essential oils
JP2023532621A (ja) 抗菌抗ウイルス性医薬組成物およびその使用
CN103802579A (zh) 一种具有多种传统功能的中药锦囊
CN1475204A (zh) 经口、鼻给药的组合物、干粉吸入剂、喷雾剂、喷雾剂辅助制剂及其制备方法
CN104255832B (zh) 一种驱蚊中药组合物及其应用
CN103110310A (zh) 一种中药保健养生枕头
CN101613637A (zh) 一种用于香囊、香枕的芳香组合物
CN104174056B (zh) 一种除甲醛中药固体空气清新剂
JP2005187394A (ja) 漢方生薬エキス含有組成物及びそれを含有する製剤
CN105123815A (zh) 一种驱蚊虫的中药香囊
CN104257752B (zh) 一种治疗鼻炎的药物组合物及其用途
WO2004043436A1 (fr) Aerosol a usage medical comprenant une huile essentielle provenant d'une plante et sa preparation
CN103566202A (zh) 有助睡眠的中药
CN107456557A (zh) 基于精油的芳香疗法制剂以及用于施用这类制剂的装置
US8821948B2 (en) Therapeutic, bio-affecting and body treating composition
CN104224925B (zh) 一种驱蚊止痒中药组合物及其应用
CN1520846A (zh) 带有植物芳香气息的速效气雾剂及其制备方法
CN112450702A (zh) 一种中药线香及其制备方法
CN108245658A (zh) 一种多功能药艾制品及其制备方法
CN107080885A (zh) 一种定量释放香气的肺功能改善装置
CN105848666A (zh) 疼痛缓解制剂以及治疗方法
JP3659665B2 (ja) 発想促進剤
AU2019200397B2 (en) Inhaling fragrance, perfume, and food flavoring
CN1394596A (zh) 经口、鼻给药的组合物、喷雾剂、辅助制剂及其制备方法

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP